Harvard Apparatus Regenerative Technology (HART), President & CEO, Jim McGorry explains the company’s focus on developing bio-engineered organs for lung & esophageal cancer and life threatening conditions of the trachea.
HART develops bio-engineered organs. It sounds like science fiction but it’s becoming a science reality. We’re focusing on restoring organ function for esophageal cancer, central lung cancer and life threatening conditions of the trachea. Our cell-frame technology is truly groundbreaking. We use the body’s own cells that we then implant on a 3D scaffold it allows for being accepted by the body, it allows for the body to guide tissue regeneration and to restore organ function. By using the patient’s own cells you avoid the potential of an immune response. Our first generation product extended life by a year to two years with patients that were originally diagnosed with a month to live. Our second-generation product has improved the properties and expanded the markets to the esophagus and the main stem bronchus. Collaboration is a major part of our company, currently we have a fantastic collaboration with the MAYO clinic, one of the world leaders with regenerative medicine. And we’re also collaborating with Conneticut Children’s Hospital. We’re participating across billion dollar markets. Those markets have a tremendous unmet medical need and we will look to file with the FDA in 2016 for our first of hopefully many indications.